Pharma Foods International Co., Ltd. Stock

Equities

2929

JP3802310007

Biotechnology & Medical Research

Delayed Japan Exchange 09:24:26 2024-04-24 pm EDT 5-day change 1st Jan Change
839 JPY +1.45% Intraday chart for Pharma Foods International Co., Ltd. 0.00% -16.27%
Sales 2022 60.18B 387M Sales 2023 68.57B 441M Capitalization 48.34B 311M
Net income 2022 -374M -2.41M Net income 2023 3.08B 19.83M EV / Sales 2022 0.84 x
Net Debt 2022 8.01B 51.56M Net Debt 2023 3.79B 24.39M EV / Sales 2023 0.76 x
P/E ratio 2022
-114 x
P/E ratio 2023
15.7 x
Employees 670
Yield 2022
1.37%
Yield 2023
1.31%
Free-Float 69.94%
More Fundamentals * Assessed data
Dynamic Chart
Pharma Foods International Co., Ltd. Provides Consolidated Earnings Guidance for the Full Year Ending July 31, 2024 CI
Pharma Foods International Co., Ltd. Announces Dividend for the Second Quarter of the Fiscal Year Ending July 31, 2024, Payable on April 2, 2024 CI
Tranche Update on Pharma Foods International Co., Ltd.'s Equity Buyback Plan announced on January 5, 2024. CI
Pharma Foods International Co., Ltd.'s Equity Buyback announced on January 5, 2024, has closed with 874,100 shares, representing 3.03% for ¥999.9 million. CI
Pharma Foods International Co., Ltd. announces an Equity Buyback for 1,100,000 shares, representing 3.8% for ¥1,000 million. CI
Pharma Foods International Co., Ltd. authorizes a Buyback Plan. CI
Pharma Foods International Return to the Black in Fiscal Q1 MT
Pharma Foods International Co., Ltd. Provides Dividend Guidance for the Second Quarter of Fiscal Year Ending July 31, 2024 CI
Pharma Foods International Co., Ltd. Provides Dividend Guidance for the Year Ending July 31, 2024 CI
Pharma Foods International Co., Ltd. Provides Consolidated Earnings Guidance for the Year Ending July 31, 2024 CI
Pharma Foods International Co., Ltd. agreed to acquire Healthcare Mail Order Business Of Daicel from Daicel Corporation. CI
Pharma Foods International Co., Ltd. Provides Consolidated Earnings Guidance for the Year Ending July 31, 2024 CI
Pharma Foods International Co., Ltd. Reports Dividend Result for the Second Quarter Ending July 31, 2023; Provides Dividend Guidance for the Second Quarter Ending July 31, 2024 CI
Pharma Foods International Co., Ltd. Reports Dividend Result for year Ending July 31, 2023, Payable on October 26, 2023 CI
Pharma Foods International Co., Ltd. Expects Dividend for the Year Ending July 31, 2024 CI
More news
1 day+1.45%
Current month-10.84%
1 month-8.31%
3 months-16.93%
6 months-36.10%
Current year-16.27%
More quotes
1 week
805.00
Extreme 805
847.00
1 month
800.00
Extreme 800
978.00
Current year
800.00
Extreme 800
1 243.00
1 year
800.00
Extreme 800
2 344.00
3 years
800.00
Extreme 800
3 605.00
5 years
427.00
Extreme 427
3 820.00
10 years
115.50
Extreme 115.5
3 820.00
More quotes
Managers TitleAgeSince
President 76 97-08-31
Chief Administrative Officer 51 -
Director/Board Member 47 16-01-31
Members of the board TitleAgeSince
Director/Board Member 68 15-09-30
President 76 97-08-31
Director/Board Member 47 03-11-30
More insiders
Date Price Change Volume
24-04-24 839 +1.45% 69 000
24-04-24 827 +0.12% 137,000
24-04-23 826 -0.84% 120,900
24-04-22 833 +3.09% 158,600
24-04-19 808 -3.69% 196,600

Delayed Quote Japan Exchange, April 24, 2024 at 09:24 pm EDT

More quotes
Pharma Foods International Co., Ltd. is a Japan-based company mainly engaged in mail order business and functional materials business. The Company operates through three business segments. The Mail Order segment is engaged in the sale of supplement Tamagosamin, cosmetics Pearl Skin Lanchel and Derma QII Mild Peeling Gel, through advertising media such as televisions and radios. The Functional Materials segment is engaged in the development and sale of functional materials such as GABA, Bonepep, Folic Acid eggs and Chicken Egg Antibody. The Company is also engaged in the planning and sale of original equipment manufacturer (OEM) products such as supplements and beverages. The Biomedical segment is engaged in the antibody contract manufacture business for drug discovery and diagnostics, and life science information (LSI) business for analysis and efficacy evaluation test of materials and products.
More about the company

Annual profits - Rate of surprise